Get started

Piramalpharma

Bullish Momentum for Piramal Pharma Above 235, Targeting 285+Details: Asset: Piramal Pharma Limited (PIRAMALPHARMA) Breakout Level: 235 Potential Target: 285+ with potential for further gains Stop Loss: Below 235 or as per risk tolerance Timeframe: Short to medium-term Rationale: Piramal Pharma has shown strong bullish momentum above the 235 level, and it is now targeting 285. The stock's technical indicators suggest continued strength, positioning it for a further upward move if it sustains this breakout. Market Analysis: Technical Setup: Breaking and sustaining above 235 suggests an ongoing bullish trend, with 285 as the immediate target. Bullish Indicators: Price action above 235 with significant buying volume implies a bullish sentiment that could drive the stock even higher. Price Target: The initial target is 285, with room for further gains if momentum continues. Risk Management: A stop loss below 235 is recommended to manage risk in case of reversal. Timeframe: The move towards 285+ is expected in the short to medium-term, subject to sustained buying pressure and market support. Risk-Reward Ratio: Favorable, with limited downside below 235 and strong upside potential, making it a bullish setup for near-term gains. Monitor market trends and volume to confirm sustained bullish momentum and consider the broader market sentiment as you track Piramal Pharma’s movement.
NSE:PPLPHARMALong
by CyborgTradingHub
1
Breakout From Tight Consolidation Range With VolumesNSE:PPLPHARMA today broke from the Narrow Consolidation Phase. After the previous Breakout in the consolidation phase, letting the 50 EMA Catch up, There Was continuous accumulation, as you can see from the volume intensity in the range. Today, on the back of magnificent Q2 FY 24-25 results, The Stock has blasted to a new All-Time High. View: Although the Stock is Overvalued at 588 P/E. Investors Should do Stock SIP or Buy on DIPS and Traders Should Wait for a Retracement to 50 EMA or a Good Consolidation Going Forward. NSE:PPLPHARMA is part of the Piramal group of companies. The company operates through 3 major segments. 1) Contract development and manufacturing organisations (CDMO) 2) Complex hospital generics (critical care) 3) Consumer Healthcare, Over-the-Counter (OTC) NSE:PPLPHARMA entered the Pharma space in 1988 with the acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions and various organic initiatives. In 2010 the Domestic formulations business was sold to About $3.7 billion and Diagnostic Services were sold to Super Religare Laboratories (SRL). 🙋‍♀️🙋‍♂️If you have any questions about this stock, feel free to reach out to me. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FLLOW for more 👍BOOST if useful ✍️COMMENT Below your views. Meanwhile, check out my other stock ideas below until this trade is activated. I would love your feedback. Disclaimer: This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:PPLPHARMALong
by Karanshah137
PPLPHARMA STRONG BULLISH CANDLEPiramal Pharma Ltd Strong Bulish candle formation after QTR Result of company good QTR result and breakout found on chart good levels for entry after a pullback or INTRADAY continuation trade with strict Stop Loss **Disclaimer:** This information is for educational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Always do your own research and consult with a financial advisor before making investment decisions.
NSE:PPLPHARMALong
by rajatbhawra
1
PIRAMAL PHARMAPPL offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan (now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little's, Tetmosol, i-Pill and Polycrol.
BSE:PPLPHARMALong
by CannySunny
PIRAMAL PHARMA (Looks Ready For 167, 195 Levels)PIRAMAL PHARMA is in uptrend since 60-61 level. The stock might achieve 167, 195 levels in the coming few months. Also, a good volume buildup can be seen on the weekly chart since last few session. The level of 142 can act as a support level. Disclaimer: I am not a SEBI registered analyst. All the stocks are for educational purposes. Investors must consult a financial advisor before making any investment. It is not a buy or sell recommendation.
NSE:PPLPHARMALong
by onkarsoundankar